Bausch Health (BHC)
(Delayed Data from NYSE)
$9.38 USD
+0.18 (1.96%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $9.40 +0.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.38 USD
+0.18 (1.96%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $9.40 +0.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) Q1 earnings surpass estimates, while revenues miss the same. The increase in guidance was impressive.
Bausch Health (BHC) Q1 Earnings Top Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 15.73% and -1.19%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Bausch Health (BHC) Q1 Earnings?
by Zacks Equity Research
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.
Bausch Health (BHC) Reports Next Week: What Awaits?
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Bausch Health (BHC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs
by Zacks Equity Research
Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.
Is Bausch Health (BHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
All You Need to Know About Bausch (BHC) Rating Upgrade to Buy
by Zacks Equity Research
Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?
by Zacks Equity Research
Aerie (AERI) gains momentum on the back of the FDA approval of its second drug, Rocklatan.
Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
by Zacks Equity Research
Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.
Why Is Bausch (BHC) Up 8.3% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Bausch Health Companies (BHC) a Great Stock for Value Investors?
by Zacks Equity Research
Is Bausch Health Companies (BHC) a great pick from the value investor's perspective right now? Read on to know more.
Aerie (AERI) Q4 Earnings Miss, Rhopressa Gains Traction
by Zacks Equity Research
Aerie (AERI) reports wider-than-expected Q4 loss. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.
Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 19.32% and 1.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
Investors are looking forward to Salix and Bausch+Lomb's performance, and other pipeline updates when Bausch (BHC) reports Q4 results on Feb 20.
Earnings Preview: Bausch Health (BHC) Q4 Earnings Expected to Decline
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch (BHC) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for February 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.
Is Bausch Health (BHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Has Bausch Health Cos (BHC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BHC) Outperforming Other Medical Stocks This Year?
Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.
Why Bausch (BHC) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bausch Health (BHC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed at $22.34 in the latest trading session, marking a +0.4% move from the prior day.